First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
- Conditions
- Solid Tumor, Adult
- Interventions
- Biological: IO-108 + cemiplimab combination therapyBiological: IO-108Biological: IO-108 + pembrolizumab combination therapy
- Registration Number
- NCT05054348
- Lead Sponsor
- Immune-Onc Therapeutics
- Brief Summary
The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a dose of IO-108 that is safe and efficacious to be tested in patients with various solid tumors.
- Detailed Description
In the Part 1 Dose Escalation, safety and tolerability of varying doses of IO-108 as monotherapy or in combination with pembrolizumab will be studied, in order to determine a proposed RP2D. In Part 2 Dose Expansion, patients with various types of solid tumors will be dosed with either IO-108 alone or in combination with either pembrolizumab or cemiplimab in order to study safety, tolerability and preliminary efficacy of IO-108 monotherapy and combination with a PD-1 inhibitor. In Part 3, a tumor type that has been studied in the Dose Expansion will be selected and patients will be randomized into 2 doses of IO-108 in order to explore safety, toxicity, efficacy relationship with exposure, in order to explore different doses of IO-108 that is safe and efficacious. Safety, PK, PD biomarkers and efficacy will be studied.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 91
- Patients must be ≥18.
- Has any histologically- or cytologically confirmed advanced/metastatic solid tumor by pathology report and has received, has been intolerant to, or has been ineligible for standard systemic therapy known to confer clinical benefit. Solid tumors of any type are eligible for enrollment. Patients with asymptomatic central nervous system (CNS) disease may be enrolled.
- Patient has measurable disease by Response Evaluation in Solid Tumors version 1.1 (RECIST 1.1) as assessed by local site.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Patients must have adequate hepatic function and renal function.
-
Patients who previously received a monoclonal antibody therapy targeting LILRB2/ Immunoglobulin-Like Transcript 4 (ILT4) (including IO-108).
-
Patients who received a biologic systemic anti-cancer therapy <4 weeks or 5 half-lives prior to their first day of study drug administration, or a small molecule systemic anti-cancer therapy or definitive radiotherapy <2 weeks or 5 half-lives prior to their first day of study drug administration or have not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or better from any adverse events (AEs) that were due to prior cancer therapeutics. Palliative radiation is allowed within 2 weeks of the first day of study drug administration.
-
Requires systemic corticosteroids at a dose of >10 mg prednisone or the dose equivalent to other systemic corticosteroid.
-
History of radiation pneumonitis, non-infectious pneumonitis or interstitial lung disease.
-
Symptomatic CNS spread of tumor.
-
History of Grade > 3 immune-related AEs with any prior immunotherapy.
-
Patients with uncontrolled, active infection.
-
Patients with known hypersensitivity to any of the components of the IO-108 formulation or pembrolizumab.
-
Active known malignancy with the exception of any of the following:
- Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer;
- Low-risk prostate cancer for which observation or hormonal therapy only is indicated;
- Any other malignancy treated with curative intent with the last treatment completed ≥6 months before study initiation (with the exception of hormonal therapies when indicated).
-
Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan ≤28 days prior to Cycle 1 Day 1 (C1D1).
-
Any of the following in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, clinically significant arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF (NYHA class III or IV), cerebrovascular accident, transient ischemic attack, or pulmonary embolism. Patients with asymptomatic right bundle branch block or controlled atrial fibrillation are allowed.
-
Ongoing cardiac dysrhythmias of Grade 2 or higher per NCI CTCAE, Version 5.0.
-
Known active bacterial, viral, and/or fungal infection including hepatitis B (HBV), hepatitis C, human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or acquired immunodeficiency syndrome (AIDS)-related illness.
-
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description IO-108 + cemiplimab combination therapy IO-108 + cemiplimab combination therapy Treatment of patients with advanced solid tumors with IO-108 in combination with a fixed dose of cemiplimab IO-108 Monotherapy IO-108 Treatment of patients with advanced solid tumors with IO-108 monotherapy IO-108 + pembrolizumab combination therapy IO-108 + pembrolizumab combination therapy Treatment of patients with advanced solid tumors with IO-108 in combination with a fixed dose of pembrolizumab
- Primary Outcome Measures
Name Time Method Incidence of treatment-emergent and serious adverse events in patients treated with IO-108 and IO-108+pembrolizumab From first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment date or disease progression whichever is earlier safety and tolerability as measured by the incidence of treatment-emergent adverse events and serious adverse events
Determine MTD (maximum tolerated dose) through assessment of dose-limiting toxicities (DLT) From the first dose of IO-108 until 21 days post-treatment MTD will be determined through observation of pre-determined DLTs in each dose cohort
Assess safety and tolerability of the IO-108 RP2D as monotherapy or in combination with either pembrolizumab or cemiplimab in patients with solid tumors From the first dose of IO-108 until the end of treatment which is up to 2 years from the first treatment or disease progression, whicheer is earlier safety and tolerability as measured by the incidence of treatment-emergent adverse events and discontinuation due to TEAEs
- Secondary Outcome Measures
Name Time Method Immunogenicity of IO-108 and IO-108+pembrolizumab From the first dose until 30 days after the last treatment Determine the incidence/titer of anti-drug antibodies (ADAs) against IO-108 and pembrolizumab (in combination treatment)
Maximum plasma concentration (Cmax) of IO-108 From the first dose of IO-108 until day 15 post-treatment Characterize the Cmax of IO-108 by successive sampling of blood at pre-specified time points
Anti-tumor activity of IO-108 and IO-108+pembrolizumab From the date of first treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to estimated period of 48 months Determine preliminary rates of response after treatment with IO-108
Determine disease control rates of IO-108 as monotherapy or in combination with either pembrolizumab or cemiplimab From the first dose of IO-108 until the last treatment which is up to 2 years from the first treatment or disease progression whichever is earlier Disease control rate is defined as the percentage of patients with complete response, partial response or stable disease maintained for at least 3 months
Steady state concentration of IO-108 From the second dose of IO-108 until the last treatment which is up to 2 years from the first treatment date Characterize steady state concentration of IO-108 by successive sampling of blood at pre-specified time points
Trial Locations
- Locations (24)
Florida Cancer Specialists & Research Institute (103)
🇺🇸Sarasota, Florida, United States
Maryland Oncology Hematology, PA (145) (USOR SITE)
🇺🇸Columbia, Maryland, United States
Gabrail Cancer Center (128)
🇺🇸Canton, Ohio, United States
Texas Oncology - Baylor Charles A. (143) (USOR SITE)
🇺🇸Dallas, Texas, United States
NEXT Oncology-Virginia (121)
🇺🇸Fairfax, Virginia, United States
Swedish Cancer Institute (147)
🇺🇸Seattle, Washington, United States
MD Anderson Cancer Center (101)
🇺🇸Houston, Texas, United States
Oncology Consultants, P.A. (138)
🇺🇸Houston, Texas, United States
Oncology Hematology Care Clinical Trials, LLC (144) (USOR SITE)
🇺🇸Cincinnati, Ohio, United States
Karmanos Cancer Institute (126)
🇺🇸Detroit, Michigan, United States
Beverly HIlls Cancer Center (129)
🇺🇸Beverly Hills, California, United States
Arizona Oncology Associates, PC-HOPE (140) (USOR SITE)
🇺🇸Tucson, Arizona, United States
Rocky Mountain Cancer Centers, LLP (141) (USOR SITE)
🇺🇸Lone Tree, Colorado, United States
Florida Cancer Specialists (134)
🇺🇸Lake Mary, Florida, United States
Memorial Cancer Institute (146)
🇺🇸Pembroke Pines, Florida, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center (123)
🇺🇸Indianapolis, Indiana, United States
Hematology Oncology (136)
🇺🇸Stuart, Florida, United States
NYU Langone Health (131)
🇺🇸New York, New York, United States
Carolina BioOncology (102)
🇺🇸Huntsville, North Carolina, United States
Providence Cancer Institute (104)
🇺🇸Portland, Oregon, United States
UPMC Hillman Cancer Center (105)
🇺🇸Pittsburgh, Pennsylvania, United States
St. Vincent - Frontier Cancer Center (135)
🇺🇸Billings, Montana, United States
University of Florida (125)
🇺🇸Gainesville, Florida, United States
Texas Oncology - Austin (142) (USOR SITE)
🇺🇸Austin, Texas, United States